Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEDQ
- Development stage
- Preclinical
- Lead developer
- Reber Genetics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PEDQ is a recombinant protein subunit vaccine developed by Reber Genetics for the prevention of Porcine Epidemic Diarrhea (PED) in swine. The vaccine is produced using a proprietary subunit technology platform that applies principles of cancer immunotherapy to animal health, presenting specific Porcine Epidemic Diarrhea virus (PEDV) antigens to induce a protective immune response. PED is a highly contagious viral disease characterized by severe enteric distress, vomiting, and high mortality rates in neonatal piglets, posing a significant economic threat to the swine industry. As of 2019, a New Drug Application (NDA) for PEDQ was filed in Taiwan.
- Other names
- PEDPED virus subunit vaccinePorcine Epidemic Diarrhea virus subunit vaccine
Beyond the preview
Go deeper on PEDQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEDQ.